癌症复发时的克隆多样性
Clonal Diversity at Cancer Recurrence
AI总结:
本研究使用两类型分支过程建模癌症复发时耐药细胞的克隆多样性,分析克隆数量和 Simpson 指数,发现早期复发源于大量耐药突变而非单一突变,为复发性癌症治疗提供新见解。
摘要:
尽管初期治疗取得成功,但癌症疗法常常因耐药细胞的出现而失败。在本研究中,我们使用数学模型研究癌症随时间的演化,特别关注肿瘤在治疗后复发时的状态。我们使用两类型分支过程来捕捉药物敏感细胞和耐药细胞的动态。我们分析了癌症复发时耐药细胞的克隆多样性,复发被定义为耐药细胞种群规模首次超过药物敏感细胞初始种群规模的指定比例。我们考察了两个克隆多样性指标:克隆数量和 Simpson 指数。我们计算了这些指标的期望值,并利用它们开发了用于估计模型参数的统计方法。此外,在敏感种群确定性衰减的特殊情况下,我们考察了以早期复发为条件的这两个指标,旨在解决早期复发是由产生异常庞大耐药细胞家族的单个突变驱动(对应低克隆多样性),还是由导致耐药的异常大量突变引起(对应高克隆多样性)的问题。基于这两个指标的研究结果支持后一种可能性。此外,我们证明癌症复发时间可作为克隆多样性的重要指标,为复发性癌症的治疗提供新见解。
英文摘要:
Despite initial success, cancer therapies often fail due to the emergence of drug-resistant cells. In this study, we use a mathematical model to investigate how cancer evolves over time, specifically focusing on the state of the tumor when it recurs after treatment. We use a two-type branching process to capture the dynamics of both drug-sensitive and drug-resistant cells. We analyze the clonal diversity of drug-resistant cells at the time of cancer recurrence, which is defined as the first time the population size of drug-resistant cells exceeds a specified proportion of the initial population size of drug-sensitive cells. We examine two clonal diversity indices: the number of clones and the Simpson's Index. We calculate the expected values of these indices and utilize them to develop statistical methods for estimating model parameters. Additionally, we examine these two indices conditioned on early recurrence in the special case of a deterministically decaying sensitive population, with the aim of addressing the question of whether early recurrence is driven by a single mutation that generates an unusually large family of drug-resistant cells (corresponding to a low clonal diversity), or if it is due to the presence of an unusually large number of mutations causing drug resistance (corresponding to a high clonal diversity). Our findings, based on both indices, support the latter possibility. Furthermore, we demonstrate that the time of cancer recurrence can serve as a valuable indicator of clonal diversity, offering new insights for the treatment of recurrent cancers.
机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。